26 completed, 12 active not recruiting, 9 recruiting, 7 terminated. 62 Phase 2, 4 Phase 3, 3 Phase 1.
Follow Degarelix: new trials by email Literature Review of Degarelix trials Research Report on Degarelix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer Androgen Deprivation Therapy (ADT), Radiotherapy - Prostate Cancer | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-08-06 | 2026-09-03 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer BMS-986165, Degarelix - Prostate Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2026-01-09 | 2026-10-05 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer ADT, Enzalutamide, Talazoparib - Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-06-03 | 2026-11-02 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer Darolutamide, Degarelix, Radiation Therapy - Prostate Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 208 | 2024-07-02 | 2024-01-24 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer Copanlisib, Degarelix, Radical Prostatectomy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2024-01-11 | 2024-10-31 | |
| ETHAN - ET for Male BC Tamoxifen, Anastrozole, Degarelix - Male Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 2 | Recruiting | Jose Pablo Leone | 60 | 2023-10-11 | 2026-08-24 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel - Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2022-01-25 | 2025-12-04 |
| Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Degarelix, pTVG-AR, Nivolumab - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Wisconsin, Madison | 57 | 2021-12-16 | 2026-09-30 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 70 | 2021-05-04 | 2026-01-28 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization Degarelix, Saline - COVID-19 | Phase 2 | Completed | VA Office of Research and Development | 96 | 2020-07-06 | 2022-06-06 |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Androgen Deprivation Therapy, Nivolumab, Docetaxel - Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Xiao X. Wei, MD | 47 | 2020-05-11 | 2026-08-12 |
| Cardiovascular Events in GnRH Agonist vs. Antagonist Degarelix, GnRH agonist - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 2 | Unknown | Rabin Medical Center | 80 | 2020-01-17 | 2019-12-02 |
Showing 20 of 62. Sign in to see all of them.
Prostatic Neoplasms (51) · Prostatic Hyperplasia (2) · Breast Neoplasms, Male (1) · COVID-19 (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Cardiovascular Diseases (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1)
Ferring Pharmaceuticals (16) · Memorial Sloan Kettering Cancer Center (5) · M.D. Anderson Cancer Center (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Astellas Pharma Inc (2) · British Columbia Cancer Agency (2) · City of Hope Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mark Stein (2) · The University of Texas Health Science Center, Houston (2) · University Health Network, Toronto (2) · Baptist Health South Florida (1) · ETOP IBCSG Partners Foundation (1) · Jonsson Comprehensive Cancer Center (1) · Jose Pablo Leone (1)
United States (40) · Canada (11) · Germany (6) · Romania (6) · Belgium (5) · Russia (5) · Hungary (4) · Netherlands (4) · United Kingdom (4) · Finland (3) · France (3) · Japan (2) · South Africa (2) · Czechia (1) · Denmark (1)
Jingsong Zhang, MD, PhD (2) · Mark N. Stein, MD (2) · Samuel Denmeade, MD (2) · Alejandro Berlin, MD (1) · Amado Zurita-Saavedra, MD (1) · Ana M. Aparicio, MD (1) · Arthur Hung (1) · Christopher Logothetis (1) · Dana Rathkopf, MD (1) · David Margel, MD, PhD (1) · Douglas McNeel, MD (1) · Eleni Efstathiou (1) · Elizabeth Kessler, MD (1)
PMID 34350976, PMID 18538469, PMID 18801505, PMID 21788033, PMID 27756786, PMID 29398594, PMID 29606109, PMID 30589600, PMID 34225789, PMID 35438754, PMID 37922910, PMID 41781018, PMID 42117295
2008 (1), 2016 (1), P30CA015704 (1), P30CA033572 (1), P50CA269011 (1), P50CA272391 (1), R01CA286127 (1), R01CA300454 (1), U10CA180868 (1)